U.S. Energy Services Stock News

In February 2026, Western Midstream Partners reported fourth-quarter 2025 results that increased revenue to US$1,031.48 million but saw net income fall to US$187.18 million, while issuing 2026 guidance that includes adjusted EBITDA of US$2.5–2.7 billion and lower capital spending of US$850 million to US$1 billion. Alongside these results, the partnership raised its 2026 distribution guidance to at least US$3.70 per unit, including a planned quarterly increase to US$0.93 per unit starting...

Amentum Holdings (AMTM) has been attracting fresh attention after securing a contract to support the UK Ministry of Defence’s hypersonic weapons program, along with roughly US$1b in nuclear sector awards in FQ1 2026. See our latest analysis for Amentum Holdings. Amentum’s recent client wins in hypersonics and nuclear awards arrive after a mixed stretch for the stock, with a 16.5% 1 month share price decline but a 62% 1 year total shareholder return from today’s US$29.87 level. If this defence...

Belite Bio (BLTE) shares are under the spotlight after the company reported a fourth quarter net loss of US$25.32 million and a full year net loss of US$77.61 million, both above prior-year levels. See our latest analysis for Belite Bio. Despite the wider losses, Belite Bio’s share price has shown strong momentum, with a 26.16% 90 day share price return and a very large 1 year total shareholder return that sits near 5x. This may point to shifting expectations around its pipeline rather than...

Lucid Group (LCID) has come under fresh scrutiny after reporting a wider fourth quarter 2025 loss, workforce cuts of 12% in its U.S. salaried staff, and revised 2025 production figures. See our latest analysis for Lucid Group. The earnings miss, production revision and workforce cuts have coincided with a 1 year total shareholder return decline of 52.83% and a 3 year total shareholder return decline of 88.66%. The 90 day share price return decline of 22.36% suggests selling pressure has been...

In recent months, several law firms have filed securities class action lawsuits against Varonis Systems, alleging the company misled investors about its ability to convert customers to its SaaS platform and sustain ARR growth between February 4, 2025 and October 28, 2025. This legal pressure highlights a tension between the bullish long-term thesis on Varonis’ role in data-centric cybersecurity and fresh questions about the reliability of its past growth disclosures. We'll now examine how...

Septerna stock: recent moves and what they might mean for investors Septerna (SEPN) has attracted attention after a month return of about 24% and a past 3 months return above 10%, prompting investors to reassess how its clinical-stage biotech profile aligns with this recent share performance. See our latest analysis for Septerna. The recent 24.3% 1 month share price return, alongside a 10.9% 3 month share price return and a very large 1 year total shareholder return, suggests momentum has...

What USA Compression Partners stock’s recent performance suggests USA Compression Partners (USAC) has drawn investor interest after a period where the unit price showed a 1 day decline of about 1%, set against positive returns over the past month and the past 3 months. See our latest analysis for USA Compression Partners. That small 1 day share price pullback sits against a 30 day share price return of 5.65% and a 90 day gain of 10.97%, while the 5 year total shareholder return of 212.85%...

Hagerty, Inc. recently reported its fourth-quarter and full-year 2025 results, with sales rising to US$221.42 million for the quarter and US$845.93 million for the year, and net income improving to US$6.92 million and US$41.46 million respectively. Alongside this stronger profitability, Hagerty issued 2026 guidance that includes lower reported revenue of about US$1.28–US$1.30 billion under a new Markel fronting arrangement and an expected net loss. Against this backdrop, we’ll now explore...

BridgeBio Pharma (BBIO) is back in focus after reporting Q4 and full year 2025 results, showing sharply higher revenue alongside continued net losses as investors weigh the impact of recent clinical and commercial progress. See our latest analysis for BridgeBio Pharma. Despite the recent Q4 earnings and a series of positive Phase 3 readouts, BridgeBio Pharma’s short term share price returns have softened, with a 30 day share price return of 14.0% and year to date share price return of 15.0%...

Recent inflation data came in hotter than expected, and renewed credit risk worries hit bank stocks broadly, including First Financial Bankshares (FFIN). Investors reassessed exposure to problem loans and economically sensitive lenders. See our latest analysis for First Financial Bankshares. The recent 7.5% one day share price decline and 7.2% 7 day share price return, on a last close of US$30.93, sits alongside a mildly positive year to date share price return of 3.03%. At the same time, the...

In late February 2026, Progyny completed a share repurchase of 6,530,363 shares for US$159.4 million and filed a US$93.26 million common stock shelf registration tied to an ESOP, shortly after reporting quarterly and full-year 2025 results that showed higher sales, net income, and earnings per share than a year earlier. Despite these milestones and record 2025 revenue and adjusted EBITDA, management’s cautious 2026 revenue guidance, adjusted for a large client transition, drew attention to...

Lineage (LINE) is back in focus after reporting fourth quarter and full year 2025 results, which included a swing to a Q4 profit and a sharply smaller annual net loss, catching investors’ attention. See our latest analysis for Lineage. At a share price of US$40.52, Lineage has seen a 5.8% 7 day share price return, a 13.5% 30 day share price return, and a 14.4% year to date share price return. However, its 1 year total shareholder return of a 29.3% decline shows that recent momentum is...

Why Qnity Electronics (Q) Is Back on Investors’ Radar Qnity Electronics (Q) has drawn fresh attention after reporting Q4 2025 results that topped analyst revenue and earnings expectations, rolling out a multi year productivity plan, and approving a US$500 million share repurchase program. See our latest analysis for Qnity Electronics. The strong Q4 surprise, fresh 2026 net sales guidance and new M&A ambitions have coincided with powerful momentum, with a 30 day share price return of 31.8% and...

Ryder System recently reported fourth-quarter 2025 results that exceeded expectations and paired them with an upbeat earnings outlook for 2026, highlighting resilient performance across its logistics and vehicle services operations. This strong update comes shortly after sizable insider share sales by senior executives, drawing attention to how leadership actions align with Ryder’s growth and capital allocation plans. With Ryder’s better-than-expected quarter and optimistic 2026 guidance now...

iRhythm Holdings (IRTC) has drawn fresh attention after recent share price moves, with the stock showing a 4.6% decline over the past day and a 13.4% slide over the past month. See our latest analysis for iRhythm Holdings. The recent 1 day share price return of 4.6% decline adds to a 30 day share price return of 13.4% decline and a year to date share price return of 23.7% decline. At the same time, the 1 year total shareholder return of 22.6% shows a very different long term picture,...

In recent weeks, Olema Pharmaceuticals announced the departure of its COO and CFO, Shane Kovacs, who will remain as a consultant through August 1, 2026, while CEO Sean Bohen temporarily assumes principal financial officer responsibilities. At the same time, continued Buy ratings from Citi and new coverage from Stifel have put a spotlight on palazestrant’s commercial potential in the sizeable endocrine therapy market and growing hedge fund interest in the stock. With this context, we’ll...

In recent months, Scorpio Tankers reported strong fourth-quarter results, with net income rising to US$128.1 million and daily TCE rates increasing year over year, while shifting its balance sheet from US$3.10 billions in net debt in 2021 to roughly US$334 million in net cash by early 2026. The company complemented this financial improvement with a higher quarterly dividend of US$0.45 per share and continued investment in scrubber-fitted vessels, pointing to a focus on cash returns and...

Preferred Bank (PFBC) has drawn fresh attention after recent trading left the stock around $87.72. Mixed returns over the past week, month and past 3 months are prompting investors to reassess its current valuation. See our latest analysis for Preferred Bank. The recent 1 day share price decline of 3.36% and year to date share price return of negative 8.57% contrast with a 1 year total shareholder return of 3.12%. This suggests shorter term momentum has cooled even as longer term holders have...

Madison Square Garden Entertainment Corp. recently disclosed that a data breach discovered on or about December 16, 2025 exposed personal information via a vulnerability in Oracle’s eBusiness Suite, prompting legal investigations by Edelson Lechtzin LLP on behalf of affected individuals. Beyond potential legal and remediation costs, this incident puts the company’s data security and operational controls under scrutiny at a time when it relies heavily on customer trust for its live...

F&G Annuities & Life, Inc. and Voya Financial, Inc. previously announced that F&G’s annuity solutions would be distributed through Voya’s Wealth Management platform, giving Voya financial professionals access to F&G products, education and support for retirement and income protection planning. This collaboration combines F&G’s product range with Voya’s advisory reach, potentially broadening F&G’s presence in the US retirement market and deepening advisor adoption of its annuity...

Relay Therapeutics, Inc. recently reported full-year 2025 results, with revenue rising to US$15.36 million from US$10.01 million and its net loss narrowing to US$276.48 million from US$337.71 million, while also securing FDA Breakthrough Therapy designation and advancing multiple 2026 data milestones for lead asset zovegalisib. Alongside a narrower basic loss per share of US$1.61 versus US$2.36 a year earlier, the company filed a US$96.18 million common-stock shelf registration tied to an...

Astec Industries, Inc. has now reported its fourth-quarter and full-year 2025 results, with Q4 sales rising to US$400.6 million from US$359.0 million and full-year sales reaching US$1.41 billion, while net income increased to US$38.8 million for 2025 and the Board maintained a quarterly dividend of US$0.13 per share payable in March 2026. Despite Q4 net income easing year on year, the company delivered record quarterly and annual sales, beat analyst earnings and revenue expectations,...

IMAX Corporation recently reported fourth-quarter 2025 revenue of US$125.21 million and full-year 2025 revenue of US$410.21 million, with annual net income rising to US$34.88 million even as quarterly net income softened. The company paired these record box office and revenue results with ongoing global network expansion and deeper local-language and live-event content partnerships, including a new collaboration with Apple TV to screen select 2026 Formula One races in IMAX theaters. We’ll...

Chemed Corporation recently reported fourth-quarter 2025 results showing net income of US$76.75 million and full-year 2025 net income of US$265.24 million, both lower than the prior year, alongside 2026 adjusted earnings guidance of US$23.25–US$24.25 per diluted share. Despite ongoing share repurchases totaling US$2.62 billion since 2011, investors focused on pressure in VITAS and Roto-Rooter margins, including Medicare Cap constraints and water-restoration write-offs. We’ll now examine how...